Lau, L. M. S., Mayoh, C., Xie, J., Barahona, P., MacKenzie, K. L., Wong, M., Kamili, A., Tsoli, M., Failes, T. W., Kumar, A., Mould, E. V. A., Gifford, A., Chow, S., Pinese, M., Fletcher, J. I., Arndt, G. M., Khuong‐Quang, D., Wadham, C., Batey, D., Eden, G., Trebilcock, P., Joshi, S., Alfred, S., Gopalakrishnan, A., Khan, A., Grebert Wade, D., Strong, P. A., Manouvrier, E., Morgan, L. T., Span, M., Lim, J. Y., Cadiz, R., Ung, C., Thomas, D. M., Tucker, K. M., Warby, M., McCowage, G. B., Dalla‐Pozza, L., Byrne, J. A., Saletta, F., Fellowes, A., Fox, S. B., Norris, M. D., Tyrrell, V., Trahair, T. N., Lock, R. B., Cowley, M. J., Ekert, P. G., Haber, M., Ziegler, D. S., & Marshall, G. M. (2022). in vitro and in vivo drug screens of tumor cells identify novel therapies for high‐risk child cancer. EMBO molecular medicine, 14(4), n/a. http://access.bl.uk/ark:/81055/vdc_100153442468.0x000006